Sigilon Therapeutics to Present at the 40th Annual Cowen & Co. Health Care Conference

The presentation is scheduled for Tuesday, Mar. 3, at 1PM EST in the MIT room.

Sigilon’s mission is to create immune-protected, bio-engineered cells to restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, potentially liberating patients from most of the challenges associated with existing treatments for serious chronic diseases. Treatments based on Sigilon’s Shielded Living Therapeutics™ platform combine advanced cell engineering with cutting-edge innovations in biocompatible materials to pioneer a new class of medicines that have been designed to provide durable, controllable and safe treatment for chronic diseases. Sigilon’s investigational therapy for hemophilia A, SIG-001, recently received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). Sigilon expects to initiate a clinical trial of SIG-001 in the first half of 2020.

About Sigilon Therapeutics

Sigilon Therapeutics is developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s therapeutics consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005264/en/